Keybanc Maintains Overweight on Masco, Raises Price Target to $79

Keybanc analyst Kenneth Zener maintains Masco (NYSE:MAS) with a Overweight and raises the price target from $72 to $79.

byBenzinga Newsdesk

October 28, 2021

1 minute read

Keybanc analyst Kenneth Zener maintains Masco (NYSE:MAS) with a Overweight and raises the price target from $72 to $79.

Regulus Therapeutics Q3 EPS $(0.10) Misses $(0.08) Estimate

By Benzinga Newsdesk

Today, 2:55 AM

Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.08) by 25 percent. This is a 150 percent decrease over losses of $(0.04) per share from

RGLS

TFF Pharmaceuticals Enters Into CRADA With The U.S. Army And The Geneva Foundation To Develop Dry Powder Needle-free Medical Countermeasures; Terms Not Disclosed

By Benzinga Newsdesk

Today, 2:55 AM

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technologyTFF Pharmaceuticals, Inc. (NASDAQ:TFFP

TFFP

Wendy’s, REEF Announce Development Commitment For 700 Delivery Kitchens Across U.S., Canada UK bBy 2025

By Benzinga Newsdesk

Today, 2:55 AM

The Wendy's Company and REEF – the largest operator of mobility, logistics hubs and kitchens – today announced a new development commitment to open and operate 700 delivery kitchens over the next five

WEN